ARTICLE | Emerging Company Profile
MabVax: The Bs have it
January 4, 2010 8:00 AM UTC
MabVax Therapeutics Inc. hopes that by focusing on the B cell immune response and going after multiple antigens with its polyvalent therapeutic cancer vaccines, it can improve patient survival where other cancer vaccines have failed.
The company plans to start a Phase II trial of its lead vaccine to treat sarcoma in 1H10...